"The large scale Hepatocellular Carcinoma Drugs Market report analyzes the market status, growth rate, future trends, market drivers, opportunities, challenges, entry barriers, risks, sales channels, and distributors. This market research report is formed with a nice combination of industry insight, smart solutions, practical solutions and newest technology to give better user experience. Businesses can obtain details about market drivers and market restraints which assist them to take presumption about reducing or increasing the production of particular product. Global Hepatocellular Carcinoma Drugs Market report comprises of historic data, present market trends, market environment, technological innovation, upcoming technologies and the technical progress in the related industry.

An international Hepatocellular Carcinoma Drugs Market research report offers an analytical assessment of the prime challenges faced by the market currently and in the coming years, which gives idea to other market participants about the problems they may face while operating in this market over a longer period of time. With the actionable market insights included in this report, businesses can craft sustainable and cost-effective strategies. The world class Hepatocellular Carcinoma Drugs Market document gives market analysis by taking into account market structure along with forecast of the various segments and sub-segments of the Hepatocellular Carcinoma Drugs Market industry.

Data Bridge Market Research analyses a growth rate in the hepatocellular carcinoma drugs market in the forecast period 2023-2030

Explore Further Details about This Research Hepatocellular Carcinoma Drugs Market Report https://www.databridgemarketresearch.com/reports/global-hepatocellular-carcinoma-drugs-market

Hepatocellular Carcinoma Drugs Market Scope and Segmentation

REPORT METRIC

DETAILS

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug Class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Exelixis, Inc (U.S.), Merck & Co., Inc.(U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), SillaJen, Inc (South Korea), Bayer AG (Germany), Janssen Global Services, LLC (U.S.), Pfizer Inc (U.S.), CELGENE CORPORATION (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc (U.S.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd (Japan), Amgen Inc. (U.S.), Polaris Group (U.S.), Hepion Pharmaceuticals (U.S.), PROVECTUS BIOPHARMACEUTICALS, INC (U.S.)

Market Opportunities
  • Increasing Strategic Collaborations Between Organizations
  • Increasing Prevalence of Hepatocellular Carcinoma

Market Definition

Hepatocellular carcinoma (HCC) is a major kind of primary liver cancer which arises from the liver cells or hepatocytes. The disease is more prevalent in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of this condition is largely done by several imaging tests such as ultrasound, CT scan, MRI, and liver biopsy. Treatment includes ablation therapy in addition to chemotherapy, radiation therapy, and targeted drug therapy. Mjority of HCC is witnessed in patients with end-stage liver dysfunction.  

Hepatocellular Carcinoma Drugs Market Dynamics

Drivers

  • Increased Prevalence of Liver Cancer

According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with almost 40,000 Americans diagnosed with liver cancer in 2017 and above 28,000 deaths are reported from the disease. Furthermore, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza as a single agent in the second-line treatment of people suffering from hepatocellular carcinoma.

  • Rising Approval of Novel Drugs

There are several clinical advancements combined with the approval of novel drugs by the regulatory agencies for the treatment of hepatocellular carcinoma is enhancing growth of the market. For instance, in April 2017, the U.S. FDA expanded the indications of regorafenib manufactured by Bayer HealthCare Pharmaceuticals Inc., for treatment of patients suffering from hepatocellular carcinoma. The therapy showed major improvement in survival for patients after the failure of standard treatments. Furthermore, in 2017, the U.S. FDA granted accelerated approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for treating hepatocellular carcinoma.

Opportunities

  • Increasing Strategic Collaborations Between Organizations

The manufactures are focused on several strategic collaborations to jointly develop and commercialize immunotherapies that are indicated to treat wide range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. made a strategic collaboration agreement to jointly develop and commercialize several immunotherapies as single and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Additionally, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients for treating advanced hepatocellular carcinoma.

  • Increasing Prevalence of Hepatocellular Carcinoma

According to the latest research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Furthermore, as per the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) resulted in around 854,000 new cases of liver cancer and 810,000 related deaths in 2015

Reasons to Consider This Report

  • To understand the Hepatocellular Carcinoma Drugs Market landscape and identify market segments that are most likely to guarantee a strong return
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for Hepatocellular Carcinoma Drugs Market
  • Efficiently plan M&A and partnership deals in Hepatocellular Carcinoma Drugs Market by identifying market segments with the most promising probable sales
  • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form cannabis seeds market
  • Obtain market revenue forecast for Hepatocellular Carcinoma Drugs Market by various segments from 2022-2029 in regions.

Why choose Data Bridge Market Research?

  • Modern technologies, such as artificial intelligence, to provide updated industry growth.
  • DBMR team provides clients with the top notch Hepatocellular Carcinoma Drugs Market research report.
  • Interaction with research scientists and development heads to understand the nature of the Hepatocellular Carcinoma Drugs Market more precisely.
  • 24/7 availability of services.
  • Data collection from implementation vendors, service providers, and raw material suppliers to provide a clear perspective with Forecast period.

DBMR team uses very fair means to gather information that is scrutinized at every stage while structuring an influential Hepatocellular Carcinoma Drugs Market size

Browse Related Reports:   

Brain Health Supplements Market  by Size, Share, Forecasts, & Trends

Vitamin E Market  Size | Statistics Report, Share, Forecast, & Trends

Distillation Systems Market  Size, Share & Trends Analysis Report

Curcumin Market  Size and Forecasts, Share and Trends

Companion Diagnostics Market  Size, Industry Share, Forecast

Sperm Bank Market  | Size, Share, Growth

Plasma Therapy Market  Size, Trends & Growth Analysis

Digital Assurance Market  : Global Industry Analysis, size, share and Forecast

Fixed Satellite Services (FSS) Market  Value | Size, Trends,Forecast|

Automated Truck Loading System Market  Size and Share | Statistics

About Data Bridge Market Research:

 US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com

"